Skip to content

The effect of plasma injection in the ovary on the number of Follicle and oocytes, the quality of oocytes, and Anti Mullerian hormone in cases of poor ovarian function.

The effect of platelet-rich plasma injection in the ovary on the number of oocytes; Oocyte quality and antimullerian hormone in cases of poor ovarian Responses.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141217020351N11
Enrollment
44
Registered
2020-11-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility. Female infertility

Interventions

Intervention 1: Intervention group:In all patients, ovarian stimulation is initiated according to the antagonist protocol and immediately after the follicle reaches 17 mm at the same time as oocyte re
2 cc of enriched platelet solution (PRP) is injected into each ovary under anesthesia and then IVF steps are performed. Intervention 2: Control group: In this group, PRP is not performed and only rout

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: The second cycle of embryo transfer Criteria for detecting poor ovarian function based on the Bologna criterion Age less than 45 years History of having at least three oocytes in the previous cycle AMH hormone less than 1.1 ng / ml BMI less than 30kg/m2 At least ten million sperm and three percent sperm with a normal morphology

Exclusion criteria

Exclusion criteria: Immunological diseases Hematological diseases Chromosomal or genetic disorder Uterine disorders Hemoglobin level less than 11 grams per deciliter Platelets less than one hundred and fifty thousand per cubic millimeter Systemic use of corticosteroids within two weeks before the procedure Hypothyroidism Respiratory tract infections Kidney failure Endometriosis Sub mucusal myoma Asherman Syndrome Pathology of the Fallopian tubes (Hydrosalpinx) Endocrine diseases Endocrine diseases Allergic reactions The dissatisfaction of the patient to continue treatment No contraindications for pregnancy

Design outcomes

Primary

MeasureTime frame
Number of oocyte. Timepoint: Two months after the PRP. Method of measurement: Vaginal Sonography.;Antimullerian hormone. Timepoint: Two months after the PRP. Method of measurement: Blood Test.;The quality of oocyte. Timepoint: Two months after the PRP. Method of measurement: Vaginal Sonography.

Secondary

MeasureTime frame
Number of obtained of embryo. Timepoint: Two months after the PRP. Method of measurement: Embryologist diagnosis.;The quality of resulted embryo. Timepoint: Two months after the PRP. Method of measurement: Embryologist diagnosis.;Chemical Pregnancy. Timepoint: Two weeks after the embryo transfer. Method of measurement: Blood Test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Alsadat Razavi

Tehran University of Medical Sciences

dr.m.razavi1357@gmail.com+98 21 6693 9320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026